Short Interest in Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS) Increases By 180.0%

Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS) was the recipient of a large increase in short interest during the month of November. As of November 15th, there was short interest totalling 1,400 shares, an increase of 180.0% from the October 31st total of 500 shares. Based on an average daily volume of 14,600 shares, the days-to-cover ratio is presently 0.1 days.

Hedge Funds Weigh In On Tema Cardiovascular and Metabolics ETF

A hedge fund recently raised its stake in Tema Cardiovascular and Metabolics ETF stock. Sterling Investment Advisors Ltd. lifted its stake in shares of Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS) by 3.7% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 158,695 shares of the company’s stock after purchasing an additional 5,605 shares during the quarter. Tema Cardiovascular and Metabolics ETF accounts for about 1.4% of Sterling Investment Advisors Ltd.’s holdings, making the stock its 23rd largest position. Sterling Investment Advisors Ltd. owned about 6.40% of Tema Cardiovascular and Metabolics ETF worth $5,332,000 as of its most recent filing with the SEC.

Tema Cardiovascular and Metabolics ETF Stock Performance

HRTS opened at $32.50 on Friday. The firm has a market cap of $80.60 million, a P/E ratio of 32.89 and a beta of 0.93. Tema Cardiovascular and Metabolics ETF has a fifty-two week low of $26.62 and a fifty-two week high of $36.03. The firm has a 50-day moving average of $33.09 and a 200 day moving average of $33.45.

About Tema Cardiovascular and Metabolics ETF

The Tema Obesity & Cardiometabolic ETF (HRTS) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that concentrates on companies focused on the treatment of cardiovascular diseases and/or metabolic diseases from companies all around the world. Using both top-down and bottom-up stock selection, the fund identifies innovative companies deemed attractive.